Key opinion leaders from regional nuclear medicine societies, the International Atomic
Energy Agency (IAEA), and industry confronted challenges including lack of availability of …

Although the past few months have been extremely challenging for SNMMI and its members,
this has been a productive year with strong forward momentum for the society and the …

The future of radionuclide therapies and innovative research in molecular imaging/nuclear
medicine depends on a reliable, affordable, and sustainable domestic supply of …

Revision 2003 a clinical setting, and continuing education is a necessary component in
maintaining the skills required to perform the duties and tasks of the nuclear medicine …

[en] The Foundation Planning Meeting of the World Radiopharmaceutical Therapy Council
(WRPTC) was held 25th June 2001 in Toronto. The meeting was attended by nuclear …

We have developed new radiopharmaceutical therapies, created novel imaging agents,
expanded molecular imaging opportunities, and utilized artificial intelligence to assist in …

The main purpose of this book is to create a reference for the indications, contraindications,
patient selection, treatment practice, treatment side effect management, and follow-up of …

There is a growing use of radionuclide therapy for the medical care of oncology patients,
where radioactive pharmaceuticals are used to target and treat various cancer types. This …

As part of SNMMI's strategic plan, one of our goals in 2014-15 is to facilitate the translation of
new radiopharmaceuticals to the clinic, collaborating with academia, industry, other imaging …

Therapeutic applications have been a driving force be-hind nuclear medicine since its
origins in treating benign and malignant thyroid disorders in the first part of the last century …